Twenty-Five Medical Societies Join Androgen Study Group to Petition JAMA to Retract Misleading Testosterone Study

Written By: The Androgen Study Group

BOSTON, April 10, 2014 /PRNewswire/ — In an unprecedented action, twenty-five international medical societies have petitioned the Journal of the American Medical Association to retract the article that precipitated recent concerns regarding cardiovascular risks with testosterone therapy, citing “gross data mismanagement” rendering the study “no longer credible.”  Twenty-two societies have added their names since the original petition was submitted to JAMA two weeks ago. The article by Rebecca Vigen and colleagues from the University of Colorado, published in the November 13, 2013 issue of JAMA, is entitled “Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels.”  The results were widely reported as new evidence that testosterone therapy is associated with cardiovascular risks, resulting in a Food and Drug Administration safety bulletin issued January 31, 2014.

The 25 medical societies represent US and international groups dedicated to education and research in endocrinology, men’s health, andrology, and sexual medicine.  These medical societies join more than 160 of the world’s leading figures in urology, endocrinology, and andrology from 32 countries, from every continent except Antarctica. Individual signers include 8 emeritus professors, 9 journal editors, and 67 full professors.

To read the full letter, click here.

About The Androgen Study Group (ASG)

The Androgen Study Group is a newly formed multidisciplinary group of clinicians and researchers dedicated to education and accurate reporting regarding testosterone deficiency in men and its treatment.

For more information, go to www.androgenstudygroup.org.

For media inquiries please contact Lisa Fiyod at contact@androgenstudygroup.org, or 617-939-1148